Article

A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques

2021-02-07

Abstract excerpt

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Ou...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bb483a28-e8dc-5052-adf2-e05047c95d97
DOI: 10.1101/2021.02.07.429299

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaquesDOI 10.1101/2021.02.07.429299Read

Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infectionSemantic proximity Read

Rapid selection of a human monoclonal antibody that potently neutralizes SARS-CoV-2 in two animal modelsSemantic proximity Read

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesSemantic proximity Read

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylacticsSemantic proximity Read

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2Semantic proximity Read

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecovirusesSemantic proximity Read

Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity Read

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopesSemantic proximity Read

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.Semantic proximity Read

Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody librarySemantic proximity Read

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceSemantic proximity Read

Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody librarySemantic proximity Read